Literature DB >> 18571625

Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression.

Andrew A Nierenberg1, Jonathan E Alpert, Erica E Gardner-Schuster, Sheila Seay, David Mischoulon.   

Abstract

BACKGROUND: The outcome of vagus nerve stimulation (VNS) for patients with bipolar treatment-resistant depression (TRD) has not been well characterized. This study describes the outcome of VNS for bipolar TRD patients participating in the acute and longitudinal pivotal trials and compares their outcome with unipolar TRD patients in the same trials.
METHODS: Of 235 participants enrolled in the acute study, 25 (11%) were diagnosed with DSM-IV bipolar I or II disorder. A sham-controlled 12-week trial of VNS preceded 2 years of open treatment. Bipolar and unipolar subjects were compared on baseline characteristics as well as acute and long-term outcomes.
RESULTS: At baseline, bipolar TRD was as severe as unipolar TRD but with depressive episodes of shorter duration and more failed antidepressant trials/year. Acute, 1-year, and 2-year outcomes were similar for both groups, even when the definition of response for bipolar TRD was expanded to include lack of manic symptoms.
CONCLUSIONS: Bipolar TRD is a serious condition. In this hypothesis-generating analysis, VNS short- and long-term effects on bipolar and unipolar TRD were similar. Because these analyses were post hoc, these findings should not be interpreted as warranting clinical inference regarding effectiveness of VNS in patients with bipolar depression.

Entities:  

Mesh:

Year:  2008        PMID: 18571625     DOI: 10.1016/j.biopsych.2008.04.036

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  16 in total

Review 1.  Targeted electrode-based modulation of neural circuits for depression.

Authors:  Helen S Mayberg
Journal:  J Clin Invest       Date:  2009-04       Impact factor: 14.808

2.  What is the role of brain stimulation therapies in the treatment of depression?

Authors:  Daniel M Blumberger; Benoit H Mulsant; Zafiris J Daskalakis
Journal:  Curr Psychiatry Rep       Date:  2013-07       Impact factor: 5.285

Review 3.  Vagus nerve stimulation in psychiatry: a systematic review of the available evidence.

Authors:  Camelia-Lucia Cimpianu; Wolfgang Strube; Peter Falkai; Ulrich Palm; Alkomiet Hasan
Journal:  J Neural Transm (Vienna)       Date:  2016-11-16       Impact factor: 3.575

4.  Bilateral epidural prefrontal cortical stimulation for treatment-resistant depression.

Authors:  Ziad Nahas; Berry S Anderson; Jeff Borckardt; Ashley B Arana; Mark S George; Scott T Reeves; Istvan Takacs
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

Review 5.  Emerging targets for antidepressant therapies.

Authors:  Jeffrey J Rakofsky; Paul E Holtzheimer; Charles B Nemeroff
Journal:  Curr Opin Chem Biol       Date:  2009-06-06       Impact factor: 8.822

Review 6.  Publication bias, with a focus on psychiatry: causes and solutions.

Authors:  Erick H Turner
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

7.  Vagus Nerve Stimulation.

Authors:  Robert H Howland
Journal:  Curr Behav Neurosci Rep       Date:  2014-06

8.  Effects of electroacupuncture at auricular concha region on the depressive status of unpredictable chronic mild stress rat models.

Authors:  Ru-Peng Liu; Ji-Liang Fang; Pei-Jing Rong; Yufeng Zhao; Hong Meng; Hui Ben; Liang Li; Zhan-Xia Huang; Xia Li; Ying-Ge Ma; Bing Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2013-01-29       Impact factor: 2.629

9.  Vagus nerve stimulation for treatment-resistant mood disorders: a long-term naturalistic study.

Authors:  Umberto Albert; Giuseppe Maina; Andrea Aguglia; Alberto Vitalucci; Filippo Bogetto; Chiara Fronda; Alessandro Ducati; Michele Lanotte
Journal:  BMC Psychiatry       Date:  2015-03-31       Impact factor: 3.630

10.  Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS.

Authors:  Cristina Cusin; Darin D Dougherty
Journal:  Biol Mood Anxiety Disord       Date:  2012-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.